Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: A South African multi-cohort analysis

Pediatric Infectious Disease Journal

Volumn 33, Issue 6, 2014, Pages 617-622

  Technau, Karl Günter ^a   Schomaker, Michael ^b   Kuhn, Louise ^c   Moultrie, Harry ^d,e   Coovadia, Ashraf ^a   Eley, Brian ^b   Rabie, Helena ^f   Wood, Robin ^b   Cox, Vivian ^g   Vizcaya, Luisa Salazar ^h   Muchiri, Evans ^d   Davies, Mary Ann ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f STELLENBOSCH UNIVERSITY   (South Africa)

^g MÉDECINS SANS FRONTIÈRES   (Switzerland)

^h UNIVERSITY OF BERN   (Switzerland)

Author keywords

abacavir; children; first line ART; HIV

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; STAVUDINE; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ARTICLE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DRUG DOSE REGIMEN; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SOUTH AFRICA; TIME TO TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; VIROLOGY; ADOLESCENT; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; COHORT STUDIES; DIDEOXYNUCLEOSIDES; FEMALE; HIV; HIV INFECTIONS; HUMANS; MALE; SOUTH AFRICA; STAVUDINE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84901508992     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000222     Document Type: Article

References (22)

1. National Department of Health. Guidelines for the Management of HIV in Children-2nd Edition 2008. 2008 Rev. Ed. Pretoria: National Department of Health; 2008.
2. National Department of Health. Guidelines for the Management of HIV in Children-2nd Edition 2010. 2010 Rev. Ed. Pretoria: National Department of Health; 2010.
3. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access-2010 revision. 2010 Rev. Ed. Geneva: World Health Organization; 2010.
4. Van Dyke RB Wang L Williams PL; Pediatric AIDS Clinical Trials Group 219C Team. Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children. J Infect Dis. 2008;198: 1599-1608.
5. Innes S Cotton MF Haubrich R et al. High prevalence of lipoatrophy in prepubertal South African children on antiretroviral therapy: a cross-sectional study. BMC Pediatr. 2012;12:183.
6. Green H Gibb DM Walker AS et al.; Paediatric European Network for the Treatment of AIDS (PENTA). Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children. AIDS. 2007;21:947-955. (Pubitemid 46684326)
7. National Department of Health. Policy and Guidelines for the Implementation of the PMTCT Program. 2008 Ed. Pretoria: National Department of Health; 2008.
8. Technau KG Lazarus E Kuhn L et al. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children. Pediatr Infect Dis J. 2013;32:851-8 55.
9. Davies MA Keiser O Technau K et ali International Epidemiologic Databases to Evaluate AIDS Southern Africa (IeDEA-SA) Collaboration. Outcomes of the South African National Antiretroviral Treatment Program me for children: the IeDEA Southern Africa collaboration. S Afr Med J 2009 99 730-737.
10. White IR Royston P Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30:377-399.
11. Rubin DB. Multiple Imputation aft er 18+ Years. J Am Stat Assoc 1996;91:473-89.
12. Staszewski S Keiser P Montaner J et al.; CNAAB3005 International Study Team. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudin e in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA. 2001;285:1155-1163. (Pubitemid 32198480)
13. Sax PE Tierney C Collier AC et al.; AIDS Clinical Trials Group Study A5202 Team. Abacavir/l amivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis. 2011;204:1191-1201.
14. Kumar PN Salvato P Lamarca A et al. A randomized controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327 the ACTION St udy). AIDS Res Ther. 2009;6:3.
15. Hill A Sawyer W. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on prot ease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. HIV Med. 2009;10:527-535.
16. Violari A Cotton MF Gibb DM et al.; CHER Study Team. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233-2244.
17. Shiau S Arpadi S Strehlau R et al. Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. J Pediatr. 2013;162:1138-45 1145.e1.
18. Lilian RR Kalk E Bhowan K et al. Early diagnosis of in utero and intrapartum HIV infection in infants prior to 6 weeks of age. J Clin Microbiol. 2012;50:2373-2377.
19. Mphatswe W Blanckenberg N Tudor-Williams G et al. High frequen cy of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. AIDS. 2007;21:1253-1261. (Pubitemid 46883479)
20. Zeh C Weidle PJ Nafisa L et al. HIV-1 drug resistance em ergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med. 2011;8:e1000430.
21. Johnson VA Calvez V G ünthard HF et al. 2011 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2011;19:156-164.
22. Waters LJ Moyle G Bonora S et al. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir Ther. 2007;12:825-830. (Pubitemid 47235497)